Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine
- PMID: 2715079
- DOI: 10.1016/0360-3016(89)90298-8
Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine
Abstract
Lonidamine is a potent inhibitor of spermatogenesis and a hyperthermic sensitizer. The previous study of lonidamine and radiation using two murine tumors demonstrated that tumor cure rates were significantly increased by radiation and concomitant lonidamine. In an effort to determine the radiobiologic factors involved with the potentiating effect of radiation by lonidamine, a series of cell culture studies were carried out using multicellular tumor spheroids (MTS) of HeLa Cells. When the MTS were treated with lonidamine in combination with fractionated irradiation, remarkable enhancement of growth inhibition was observed at the drug concentration of 10 micrograms/ml. On the other hand, there was no demonstrable enhancement of growth inhibition induced by a single dose of irradiation. Although the present findings would be consistent with the inhibitory action of potentially lethal damage repair of radiation by the drug, an alternative possibility is that the cells that have received the combined treatment have undergone a metabolic change, which has altered their sensitivity to the growth inhibitory effects of lonidamine. Based on the studies reported here and in mice, it is suggested that continued drug exposure over a prolonged period may provide an enhanced therapeutic effect, even in tumor varieties where the drug has no apparent antitumor activity on nonirradiated cells.
Similar articles
-
Potentiation of radiation effects on two murine tumors by lonidamine.Cancer Res. 1986 Mar;46(3):1120-3. Cancer Res. 1986. PMID: 3943089
-
Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo.Oncology. 1984;41 Suppl 1:30-5. doi: 10.1159/000225882. Oncology. 1984. PMID: 6717892
-
Lonidamine and radiotherapy in head and neck cancers. A pilot study.Oncology. 1984;41 Suppl 1:113-5. doi: 10.1159/000225898. Oncology. 1984. PMID: 6717889
-
Lonidamine, a new approach to cancer therapy.Oncology. 1984;41 Suppl 1:2-6. doi: 10.1159/000225878. Oncology. 1984. PMID: 6371644 Review.
-
Lonidamine in malignant brain tumors.Semin Oncol. 1991 Apr;18(2 Suppl 4):38-41. Semin Oncol. 1991. PMID: 2031197 Review.
Cited by
-
The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.Cancers (Basel). 2020 Nov 11;12(11):3332. doi: 10.3390/cancers12113332. Cancers (Basel). 2020. PMID: 33187214 Free PMC article. Review.
-
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.NMR Biomed. 2015 Mar;28(3):281-90. doi: 10.1002/nbm.3240. Epub 2014 Dec 12. NMR Biomed. 2015. PMID: 25504852 Free PMC article.
-
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.Breast Cancer Res Treat. 1992;24(1):27-34. doi: 10.1007/BF01832355. Breast Cancer Res Treat. 1992. PMID: 1463869
-
Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?Cancers (Basel). 2019 Jan 18;11(1):112. doi: 10.3390/cancers11010112. Cancers (Basel). 2019. PMID: 30669417 Free PMC article. Review.
-
Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells.Int J Mol Sci. 2020 Dec 9;21(24):9367. doi: 10.3390/ijms21249367. Int J Mol Sci. 2020. PMID: 33316932 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources